TY - JOUR
T1 - Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes
T2 - 8-month prospective pilot study
AU - Rizzo, Manfredi
AU - Chandalia, Manisha
AU - Patti, Angelo M.
AU - Di Bartolo, Vittoria
AU - Rizvi, Ali A.
AU - Montalto, Giuseppe
AU - Abate, Nicola
N1 - Funding Information:
We want to thank all volunteers who participated in this trial. NA is supported by NIH Clinical and Translational Science Award UL1TR000071.
PY - 2014/2/22
Y1 - 2014/2/22
N2 - Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown.Methods: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.Results: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied.Conclusions: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations.Trial registration: ClinicalTrials.gov: NCT01715428.
AB - Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown.Methods: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.Results: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied.Conclusions: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations.Trial registration: ClinicalTrials.gov: NCT01715428.
KW - Cardiovascular risk
KW - Carotid intima-media thickness
KW - Liraglutide
KW - Type2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84895762544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895762544&partnerID=8YFLogxK
U2 - 10.1186/1475-2840-13-49
DO - 10.1186/1475-2840-13-49
M3 - Article
C2 - 24559258
AN - SCOPUS:84895762544
SN - 1475-2840
VL - 13
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
IS - 1
M1 - 49
ER -